阿尔茨海默+减肥药，阿尔茨海默领域服务欧美药企，为小分子减肥药提供中间体，客户包括礼来、辉瑞 等巨头，在中美均设有研发生产中心，这家公司可为客户提供含氟药物中间体或原料药的定制服务。 前言 《电报解读》是一款主打时效性和专业性的即时资讯解读产品。侧重于挖掘重要事件的投资价值、分析 产业链公司以及解读重磅政策的要点。即时为用户提供快讯信息对市场影响的投资参考，将信息的价值 用专业的视角、朴素的语言、图文并茂的方式呈现给用户。 ...

Core Viewpoint - Pfizer Inc. has seen a decline in its dividend yield from 7.5% in late April to approximately 6.9% currently, indicating a shift in the investment landscape for the company [1]. Company Analysis - Pfizer Inc. is currently offering a dividend yield of around 6.9%, down from 7.5% earlier in the year, which may affect investor sentiment and decisions [1]. Investment Strategy - The investment philosophy emphasizes thorough research and a long-term perspective, focusing on value stocks while maintaining exposure to growth opportunities [1].

Key Takeaways PFE has traded above its 50-day SMA since the end of May, marking a short-term bullish trend. Pfizer's new products and Seagen deal are driving growth despite falling COVID sales and patent expirations. PFE trades below its 5-year average P/E, offering value amid high dividends and cost-cutting efforts.Pfizer (PFE) has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since the end of May, the stock has been trading above its 50-da ...

随着AI与云技术的演进融合，在全球企业加速数字化转型的浪潮中，数据基础设施建设正成为企业推 动业务创新、保障合规运营的核心支柱。 在此背景下，如何构建安全合规、高效可扩展的数据基座，并借力前沿的生成式AI技术加速创新，成 为企业决胜未来的关键。尤其是对于近年来决定大幅在中国加码投资的跨国企业而言，解决在地数据化 挑战，成为业内聚焦的热点议题。 据Gartner发布的报告，全球公共云服务终端用户支出预计将在2025年达到7234亿美元，较2024年增长 21.5%。其中，基础设施即服务（IaaS）与平台即服务（PaaS）将分别增长24.8%和21.6%，显示出企业 在基础IT架构和数据平台能力上的持续加码。 在日前举行的2025亚马逊云科技中国峰会期间，辉瑞投资有限公司数字化中国交付负责人陈勇向《中国 经营报》记者分享了辉瑞中国的经验。陈勇表示，随着数据重要性越来越高，数据在资产化的过程中， 很多企业甚至现在注册的时候只有数据资产。但在现代化的数据战略构架下，基础的云架构应是高度可 扩展伸缩、安全稳定的基础设施，已成为基本共识。 与此同时，各国日趋完善的数据隐私和安全法规，如中国的《个人信息保护法》（PIPL） ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below are the ratings of the most accurate analysts for three high-yield ...

When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.Patent-protected exclusivity is the reason pharmaceutical stocks are known for delivering reliably growing dividend payments. Unfortunately, some of Pfizer's (PFE 1.08%) most important patents are expiring soon.Shares of Pfizer have been beaten down about 60% from their previous peak in 2021. The price is way down ...

Three supercharged dividend stocks have the necessary catalysts to make their patient shareholders notably richer.For more than a century, Wall Street has been a bona fide wealth-creating machine. Though other asset classes, including bonds, commodities, and real estate, have also delivered positive long-term returns, none of these other investments has come particularly close to matching the average annual return of stocks over the last 100 years.With thousands of publicly traded companies and exchange-tra ...

Company Performance - Pfizer (PFE) closed at $25.32, marking a +1.12% move from the prior day, outperforming the S&P 500 which gained 0.48% [1] - Over the past month, Pfizer's shares gained 7.24%, surpassing the Medical sector's gain of 2.8% and the S&P 500's gain of 5.13% [1] Upcoming Earnings Report - Pfizer is scheduled to release its earnings on August 5, 2025, with projected EPS of $0.57, indicating a 5.00% drop compared to the same quarter of the previous year [2] - The consensus estimate forecasts revenue to be $13.55 billion, reflecting a 2% growth compared to the corresponding quarter of the prior year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates anticipate earnings of $3.06 per share and revenue of $63.25 billion, showing shifts of -1.61% and -0.6% from the last year [3] - Recent changes to analyst estimates for Pfizer indicate a favorable outlook on business health and profitability [3] Zacks Rank and Valuation - Pfizer currently has a Zacks Rank of 3 (Hold), with a 0.04% fall in the Zacks Consensus EPS estimate over the past month [5] - The company is trading at a Forward P/E ratio of 8.18, which is a discount compared to the industry average Forward P/E of 14.05 [5] PEG Ratio and Industry Context - Pfizer has a PEG ratio of 0.91, compared to the Large Cap Pharmaceuticals industry average PEG ratio of 1.24 [6] - The Large Cap Pharmaceuticals industry is currently ranked 158 in the Zacks Industry Rank, placing it in the bottom 37% of all industries [6][7]

Market Capitalization Summary - Oracle has a market capitalization of 806.88 billion, while Visa stands at 655.99 billion [2] - Procter & Gamble has a market capitalization of 378.02 billion, and ExxonMobil is at 512.70 billion [2] - Mastercard's market capitalization is 470.87 billion, and Bank of America is at 375.11 billion [2] - UnitedHealth has a market capitalization of 308.53 billion, while ASML is at 310.77 billion [2] - Coca-Cola's market capitalization is 295.75 billion, and T-Mobile US Inc is at 273.60 billion [2] Stock Performance - Oracle's stock increased by 0.46 (+0.47%), while Visa's rose by 0.47 (+0.13%) [2] - Procter & Gamble's stock saw a slight increase of 2.68 (+0.48%), while ExxonMobil's stock increased by 1.92 (+1.20%) [2] - Mastercard's stock increased by 1.46 (+1.35%), and Bank of America's stock rose by 3.15 (+2.06%) [2] - UnitedHealth's stock decreased by 11.21 (-1.40%), while ASML's stock increased by 0.93 (+1.31%) [2] - Coca-Cola's stock increased by 14.05 (+4.50%), and T-Mobile US Inc's stock rose by 3.31 (+1.39%) [2] Additional Company Insights - McDonald's has a market capitalization of 212.78 billion, while AT&T is at 207.73 billion [3] - Uber's market capitalization is 192.79 billion, and Verizon's is at 184.08 billion [3] - Caterpillar's market capitalization is 183.87 billion, while Qualcomm is at 174.99 billion [3] - BlackRock has a market capitalization of 163.25 billion, and Citigroup is at 161.13 billion [3] - Boeing's market capitalization is 158.16 billion, while Pfizer is at 142.36 billion [3] Recent Market Movements - Intel's stock increased by 0.45 (+1.99%), while Dell Technologies rose by 0.82 (+0.16%) [4] - Rio Tinto's market capitalization is 746.07 billion, and Newmont is at 654.78 billion [4] - General Motors has a market capitalization of 494.87 billion, while Target is at 472.00 billion [4] - Ford's market capitalization is 451.14 billion, and Valero Energy is at 432.26 billion [4] - Vodafone's market capitalization is 241.45 billion, while Pinterest is at 270.30 billion [5]

Other large players in the oncology space are AstraZeneca (AZN) , Merck (MRK) and Bristol-Myers (BMY) For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Key Takeaways Pfizer (PFE) has committed significant resources for the development of treatments in the ...